1.Wacker, C, Prkno, A, Brunkhorst, FM, Schlattmann, P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426–435.
2.Uzzan, B, Cohen, R, Nicolas, P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34:1996–2003.
3.Nobre, V, Harbarth, S, Graf, JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177:498–505.
4.Hohn, A, Schroeder, S, Gehrt, A, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 2013;13:158.
5.Hochreiter, M, Köhler, T, Schweiger, AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13:R83.
6.Schroeder, S, Hochreiter, M, Koehler, T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221–226.
7.Stolz, D, Smyrnios, N, Eggimann, P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009;34(6):1364–1375.
8.Bouadma, L, Luyt, CE, Tubach, F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463–474.
9.Soni, NJ, Samson, DJ, Galaydick, JL, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013;8:530–540.
10.Matthaiou, DK, Ntani, G, Kontogiorgi, M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012;38:940–949.
11.Prkno, A, Wacker, C, Brunkhorst, FM, Schlattmann, P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care 2013;17:R291.
13.Jensen, JU, Hein, L, Lundgren, B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048–2058.
14.Feazel, LM, Malhotra, A, Perencevich, EN, et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748–1754.
15.Smith, KJ, Wateska, A, Nowalk, MP, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med 2013;28:1157–1164.
16.Michaelidis, CI, Zimmerman, RK, Nowalk, MP, Fine, MJ, Smith, KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29:579–586.
17.Heyland, DK, Johnson, AP, Reynolds, SC, Muscedere, J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792–1799.
18.Deliberato, RO, Marra, AR, Sanches, PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013;76:266–271.
19.U.S. Bureau of Labor Statistics. Consumer price index—all urban consumers medical care services. http://www.bls.gov/cpi/data.htm. Published 2014. Accessed June 17, 2014.
21.Dellinger, RP, Levy, MM, Rhodes, A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637.
23.Chastre, J, Wolff, M, Fagon, JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588–2598.
24.Elyasi, S, Khalili, H, Hatamkhani, S, Dashti-Khavidaki, S. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol 2013;69:747–754.
25.Cano, EL, Haque, NZ, Welch, VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin Ther 2012;34:149–157.
26.van Hal, SJ, Paterson, DL, Lodise, TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57:734–744.
27.Chertow, GM, Burdick, E, Honour, M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365–3370.
28.Lucado, J, Gould, C, Elixhauser, A. Statistical brief #124: Healthcare Cost and Utilization Project (HCUP) Clostridium difficile infections (CDI) in hospital stays, 2009. http://hcup-us.ahrq.gov/reports/statbriefs/sb124.jsp. Published January 2012. Accessed December 12, 2014.
30.Angus, DC, Linde-Zwirble, WT, Clermont, G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1–11.
31.Stranges, PM, Hutton, DW, Collins, CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297–304.
32.Liem, YS, Bosch, JL, Hunink, MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health 2008;11:733–741.
33.Wyld, M, Morton, RL, Hayen, A, Howard, K, Webster, AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med 2012;9:e1001307.
35.Angus, DC, Linde-Zwirble, WT, Lidicker, J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.
36.Albrich, WC, Dusemund, F, Bucher, B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715–722.
37.Schuetz, P, Raad, I, Amin, DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care 2013;19:453–460.
38.Burgess, LD, Drew, RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014;34:670–676.
39.Malani, AN, Richards, PG, Kapila, S, et al. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am J Infect Control 2013;41:145–148.
40.Feazel, LM, Malhotra, A, Perencevich, EN, et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748–1754.